Infection with human T lymphotropic virus types I and II in sexually transmitted disease clinics in Baltimore and New Orleans.
Patients attending sexually transmitted disease (STD) clinics in Baltimore (n = 4880) and New Orleans (n = 1054) were surveyed in 1987 to estimate the prevalence of human T lymphotropic virus (HTLV)-I/II infection. In Baltimore, 0.4% (95% confidence interval [CI], 0.2-1.1) were HTLV-I/II-seropositive and 4.9% were human immunodeficiency virus (HIV-1)-positive. In New Orleans, 1.8% (CI, 1.2-2.9) of sera were HTLV-I/II-seropositive and 5.1% were HIV-1-seropositive. In both cities, HTLV-I/II prevalence increased significantly with age, and the New Orleans age- and sex-adjusted HTLV-I/II prevalence was significantly higher than that of Baltimore (P less than .001). In Baltimore, almost all HTLV-I/II seropositivity was associated with a history of parenteral drug use or sexual contact with partners who were drug users or male homosexuals. In addition, individuals in both cities who were seropositive for HIV-1 or syphilis were significantly more likely to be HTLV-I/II-seropositive.
Wiktor
S Z
SZ
Viral Epidemiology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Cannon
R O
RO
Atkinson
W L
WL
Lutz
B
B
Hook
E W
EW
Blattner
W A
WA
Quinn
T C
TC
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D015142:Baltimore / Q000453:epidemiology; D005260:Female; D015483:HIV Antibodies / Q000097:blood; D015658:HIV Infections / Q000453:epidemiology*; D015497:HIV-1 / Q000276:immunology*; D015481:HTLV-I Antibodies / Q000097:blood; D015490:HTLV-I Infections / Q000453:epidemiology*; D015482:HTLV-II Antibodies / Q000097:blood; D015491:HTLV-II Infections / Q000453:epidemiology*; D006801:Humans; D008145:Louisiana / Q000453:epidemiology; D008297:Male; D015995:Prevalence; D012307:Risk Factors; D012749:Sexually Transmitted Diseases / Q000453:epidemiology*; D015819:Substance Abuse, Intravenous / Q000150:complications
D015483:HIV Antibodies; D015481:HTLV-I Antibodies; D015482:HTLV-II Antibodies